JPWO2021094331A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021094331A5
JPWO2021094331A5 JP2022516283A JP2022516283A JPWO2021094331A5 JP WO2021094331 A5 JPWO2021094331 A5 JP WO2021094331A5 JP 2022516283 A JP2022516283 A JP 2022516283A JP 2022516283 A JP2022516283 A JP 2022516283A JP WO2021094331 A5 JPWO2021094331 A5 JP WO2021094331A5
Authority
JP
Japan
Prior art keywords
composition according
pharmaceutical composition
subject
administered
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500020A5 (https=
JP2023500020A (ja
JP7808029B2 (ja
Publication date
Priority claimed from EP19382990.0A external-priority patent/EP3818983A1/en
Application filed filed Critical
Publication of JP2023500020A publication Critical patent/JP2023500020A/ja
Publication of JPWO2021094331A5 publication Critical patent/JPWO2021094331A5/ja
Publication of JP2023500020A5 publication Critical patent/JP2023500020A5/ja
Application granted granted Critical
Publication of JP7808029B2 publication Critical patent/JP7808029B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516283A 2019-11-11 2020-11-10 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物 Active JP7808029B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382990.0 2019-11-11
EP19382990.0A EP3818983A1 (en) 2019-11-11 2019-11-11 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PCT/EP2020/081674 WO2021094331A1 (en) 2019-11-11 2020-11-10 Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification

Publications (4)

Publication Number Publication Date
JP2023500020A JP2023500020A (ja) 2023-01-04
JPWO2021094331A5 true JPWO2021094331A5 (https=) 2023-10-26
JP2023500020A5 JP2023500020A5 (https=) 2023-10-26
JP7808029B2 JP7808029B2 (ja) 2026-01-28

Family

ID=68610132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022516283A Active JP7808029B2 (ja) 2019-11-11 2020-11-10 心血管石灰化の治療、進行の抑制、または予防における使用のためのイノシトールリン酸化合物

Country Status (10)

Country Link
US (2) US20220339171A1 (https=)
EP (2) EP3818983A1 (https=)
JP (1) JP7808029B2 (https=)
KR (1) KR20220099957A (https=)
CN (1) CN114585367A (https=)
AU (1) AU2020381775B2 (https=)
CA (1) CA3156023A1 (https=)
IL (1) IL292118B1 (https=)
MX (1) MX2022004971A (https=)
WO (1) WO2021094331A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018445164B2 (en) * 2018-10-11 2025-05-29 Vifor (International) Ltd. Inositol phosphates for the treatment of ectopic calcification
CN113712976B (zh) * 2021-10-21 2023-02-24 中国人民解放军海军军医大学 小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs
US20250217970A1 (en) * 2023-12-28 2025-07-03 Case Western Reserve University Risk prediction of heart failure

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
WO1997047285A1 (en) 1996-06-10 1997-12-18 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
CA2290624C (en) 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2389236A1 (en) 1999-11-02 2001-05-10 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
ES2270982T3 (es) 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP2004532259A (ja) 2001-05-29 2004-10-21 デポメッド ディベロップメント リミティド 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
CN105949234B (zh) 2011-09-29 2018-07-10 苏黎世联邦理工学院 用于治疗艰难梭菌感染的药物化合物
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) * 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
DK3386994T3 (da) 2015-12-11 2020-01-13 Eth Zuerich 4,6-di-(o-thiophosphat)-inositol-1,2,3,5-tetra-o-sulfat mod c. difficile-infektion
EA037572B1 (ru) 2015-12-11 2021-04-15 Этх Цюрих Производные инозитола для применения в патологической кристаллизации

Similar Documents

Publication Publication Date Title
JP2012529483A5 (https=)
CN109985237B (zh) 一种治疗结直肠癌的药物组合物及其应用
CN111214464A (zh) 包含15-hepe的组合物以及其使用方法
JP2010189446A (ja) 肝臓癌の発症予防のための医薬
JP2025148449A5 (https=)
JPS6287516A (ja) 悪性腫瘍の生体外での処置法
JP2022521119A5 (https=)
JP2020500868A5 (https=)
CN114392256A (zh) 矢车菊素在防治血管钙化中的应用
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
RU2006124557A (ru) Композиции и способы введения средств, связывающих тубулин, для лечения глазных заболеваний
JPWO2021094331A5 (https=)
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
CN117243956A (zh) 一种用于治疗结核分枝杆菌感染的药物组合物及其应用
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
JP2022177119A5 (https=)
JPH0121132B2 (https=)
JP5792322B2 (ja) ビタミンｄおよびメトホルミン含有医薬組成物
JP2005503323A5 (https=)
JPWO2023078333A5 (https=)
US20110117070A1 (en) Compositions and methods for treating headache
TW202038931A (zh) 使用6,8-雙-苄硫基-辛酸和自噬抑制劑治療癌症之治療方法及組成物
EP2902028A1 (en) Drug composition for treating tumors and application thereof
CN102309491B (zh) 一种替加氟、吉美斯特复方注射液
JPWO2020157362A5 (https=)